Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects

Clinical and Translational Science
Yasuyuki IshiiNaoto Uemura

Abstract

BFE1224, prodrug of ravuconazole, is a novel, once-daily, oral, triazole antifungal drug, and currently in development for the treatment of onychomycosis. The clinical drug-drug interaction (DDI) potential of BFE1224 with cytochrome P450 (CYP) and transporter was assessed by using two types of cocktails in healthy subjects in separate clinical studies. The CYP and transporter cocktails consisted of caffeine/tolbutamide/omeprazole/dextromethorphan/midazolam used in study 1 and digoxin/rosuvastatin used in study 2. In addition, repaglinide was separately administered to the same subjects in study 2. There were no major effects on the pharmacokinetics of CYP and transporter substrates, except for an approximate threefold increase in midazolam exposure after oral administration of BFE1224. The clinical DDIs of BFE1224 were mild for CYP3A and minor for other major CYPs (CYP1A2/2C8/2C9/2C19/2D6) as well as those of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, and OATP1B3.

References

May 1, 1994·Clinical Pharmacology and Therapeutics·K T OlkkolaP J Neuvonen
Nov 1, 1996·Pharmacology & Toxicology·J PartanenP J Neuvonen
Mar 1, 1997·Journal of the American Academy of Dermatology·A K GuptaB E Elewski
Apr 1, 1997·Clinical Pharmacology and Therapeutics·K M JalavaP J Neuvonen
Jan 8, 1998·Therapeutic Drug Monitoring·K M JalavaP J Neuvonen
Apr 29, 1998·Clinical Pharmacology and Therapeutics·P J NeuvonenK T Kivistö
May 26, 1999·Clinical Pharmacology and Therapeutics·S M Abdel-RahmanG L Kearns
Aug 28, 1999·The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons·B S Schlefman
Mar 1, 2002·The American Journal of Psychiatry·John P O'ReardonMartin P Szuba
Dec 5, 2002·Journal of Clinical Pharmacology·Paul D MartinDennis W Schneck
Jul 10, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nina IsoherranenKenneth E Thummel
Jul 1, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·A K GuptaUNKNOWN Ravuconazole onychomycosis group
Jan 25, 2006·Journal of Clinical Pharmacology·Jing-He YanDennis M Grasela
Nov 25, 2006·European Journal of Clinical Pharmacology·Norio Yasui-FurukoriSunao Kaneko
Jan 30, 2007·Clinical Pharmacology and Therapeutics·S-M HuangL J Lesko
Apr 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Roger J M BrüggemannDavid M Burger
Mar 31, 2010·American Journal of Obstetrics and Gynecology·Sarah J HemauerMahmoud S Ahmed
Nov 6, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xuena LinJianling Wang
Jun 3, 2016·Medical Mycology Journal·Yuichiro Tsunemi

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

WinNonlin Professional

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2022 Meta ULC. All rights reserved